AZD9793 / AstraZeneca - LARVOL DELTA

RHEA-1: First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours (clinicaltrials.gov) - P1/2 | N=304 | Recruiting | Sponsor: AstraZeneca | Trial primary completion date: Feb 2028 ➔ Jun 2027

First-in-human • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3

Advancing GPC3-positive solid tumor therapy with AZD9793, a novel CD8-guided T cell engager with potent pre-clinical efficacy and superior therapeutic index over GPC3 x CD3 formats (AACR 2025) - "The combined features of bivalent GPC3 binding, CD8-biased engagement, and low-affinity TCR binding enhance AZD9793 cytotoxic potency against tumor cells while minimizing the risk of cytokine release and associated toxicities. These findings support the ongoing clinical evaluation of AZD9793 as a promising therapeutic for patients with GPC3-positive solid tumors."

Preclinical • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • CD8 • GPC3 • IFNG

RHEA-1: First-in-human (FIH) study of AZD9793, a first-in-class CD8-guided T cell-engager (TCE) for glypican-3-positive (GPC3+) advanced or metastatic hepatocellular carcinoma (HCC). (ASCO 2025) - P1/2 | "No formal statistical hypothesis is proposed; all variables will be reported descriptively. The study (NCT06795022) is currently enrolling in the US and APAC."

IO biomarker • Metastases • P1 data • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor • CD4 • CD8 • GPC3

RHEA-1: First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours (clinicaltrials.gov) - P1/2 | N=304 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor

RHEA-1: First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours (clinicaltrials.gov) - P1/2 | N=304 | Not yet recruiting | Sponsor: AstraZeneca

New P1/2 trial • Hepatocellular Cancer • Oncology • Solid Tumor